| Autor: |
Louzada-Neto O; Universidade do Estado do Rio de Janeiro, Departamento de Bioquímica, Laboratório de Toxicologia e Biologia Molecular, Rio de Janeiro, RJ, Brazil., Lopes BA; Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil., Brisson GD; Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil., Andrade FG; Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil., Cezar IS; Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil., Santos-Rebouças CB; Universidade do Estado do Rio de Janeiro, Departamento de Genética, Rio de Janeiro, RJ, Brazil., Albano RM; Universidade do Estado do Rio de Janeiro, Departamento de Bioquímica, Laboratório de Toxicologia e Biologia Molecular, Rio de Janeiro, RJ, Brazil., Pombo-de-Oliveira MS; Centro de Pesquisas, Instituto Nacional do Câncer, Programa de Hematologia-Oncologia Pediátrica, Rio de Janeiro, RJ, Brazil., Rossini A; Universidade do Estado do Rio de Janeiro, Departamento de Bioquímica, Laboratório de Toxicologia e Biologia Molecular, Rio de Janeiro, RJ, Brazil. |
| Abstrakt: |
Early age acute leukemia (EAL) shows a high frequency of KMT2A-rearrangements (KMT2A-r). Previous investigations highlighted double-strand breaks arising from maternal exposure to xenobiotics during pregnancy as a risk factor for EAL and KMT2A-r. In this case-control study, we investigated the relationship between EAL and genetic variants of the nonhomologous end-joining (XRCC6 rs5751129, XRCC4 rs6869366 and rs28360071), since they might affect DNA repair capacity, leading to KMT2A-r and leukemogenesis. Samples from 577 individuals (acute lymphoblastic leukemia-ALL, n=164; acute myeloid leukemia-AML, n=113; controls, n=300) were genotyped. No significant association was found for rs5751129 and rs6869366, whereas rs28360071 was associated with an increased risk for ALL with KMT2A-r (IIxID: OR - Odds ratio 2.23, CI 1.17-4.25, p=0.014). Bone marrow samples from ALL patients showed a higher expression of XRCC4 compared to AML patients (p=0.025). Human Splicing Finder 3.1 predicted that the deleted allele of rs28360071 is potentially associated with the activation of a 5' cryptic splice site in intron 3 of XRCC4. The sequencing of cDNA did not show any differences on the splicing process for the rs28360071 genotypes. Our results suggest that the deleted allele for rs28360071 increases the risk for ALL with KMT2A-r, but not by modifying the XRCC4 expression levels or its structure. |
